Vetoquinol SA, a veterinary pharmaceutical company, designs, develops, and sells veterinary drugs and non-medicinal products in Europe, the Americas, and the Asia Pacific region.
Flawless balance sheet with moderate growth potential.
Share Price & News
How has Vetoquinol's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: VETO's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: VETO underperformed the French Pharmaceuticals industry which returned 10.6% over the past year.
Return vs Market: VETO exceeded the French Market which returned -14.3% over the past year.
Price Volatility Vs. Market
How volatile is Vetoquinol's share price compared to the market and industry in the last 5 years?
Simply Wall St News
4 days ago | Simply Wall StCan You Imagine How Vetoquinol's (EPA:VETO) Shareholders Feel About The 58% Share Price Increase?
2 weeks ago | Simply Wall StIs Vetoquinol (EPA:VETO) Using Too Much Debt?
1 month ago | Simply Wall StA Rising Share Price Has Us Looking Closely At Vetoquinol SA's (EPA:VETO) P/E Ratio
Is Vetoquinol undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: VETO (€54) is trading above our estimate of fair value (€44.57)
Significantly Below Fair Value: VETO is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: VETO is good value based on its PE Ratio (22.3x) compared to the Pharmaceuticals industry average (22.3x).
PE vs Market: VETO is poor value based on its PE Ratio (22.3x) compared to the French market (14x).
Price to Earnings Growth Ratio
PEG Ratio: VETO is poor value based on its PEG Ratio (1.2x)
Price to Book Ratio
PB vs Industry: VETO is good value based on its PB Ratio (1.7x) compared to the FR Pharmaceuticals industry average (2.4x).
How is Vetoquinol forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: VETO's forecast earnings growth (18.1% per year) is above the savings rate (0.6%).
Earnings vs Market: VETO's earnings (18.1% per year) are forecast to grow faster than the French market (13.1% per year).
High Growth Earnings: VETO's earnings are forecast to grow, but not significantly.
Revenue vs Market: VETO's revenue (6.8% per year) is forecast to grow faster than the French market (4% per year).
High Growth Revenue: VETO's revenue (6.8% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: VETO's Return on Equity is forecast to be low in 3 years time (9.4%).
How has Vetoquinol performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: VETO has high quality earnings.
Growing Profit Margin: VETO's current net profit margins (7.2%) are lower than last year (9.9%).
Past Earnings Growth Analysis
Earnings Trend: VETO's earnings have grown by 6.7% per year over the past 5 years.
Accelerating Growth: VETO's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: VETO had negative earnings growth (-21.2%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (7%).
Return on Equity
High ROE: VETO's Return on Equity (7.3%) is considered low.
How is Vetoquinol's financial position?
Financial Position Analysis
Short Term Liabilities: VETO's short term assets (€257.3M) exceed its short term liabilities (€92.7M).
Long Term Liabilities: VETO's short term assets (€257.3M) exceed its long term liabilities (€32.8M).
Debt to Equity History and Analysis
Debt Level: VETO's debt to equity ratio (0.4%) is considered satisfactory.
Reducing Debt: VETO's debt to equity ratio has reduced from 20.8% to 0.4% over the past 5 years.
Debt Coverage: VETO's debt is well covered by operating cash flow (3692.3%).
Interest Coverage: VETO's interest payments on its debt are well covered by EBIT (450.8x coverage).
What is Vetoquinol's current dividend yield, its reliability and sustainability?
Current Dividend Yield
Upcoming Dividend Payment
Dividend Yield vs Market
Notable Dividend: VETO's dividend (0.7%) isn’t notable compared to the bottom 25% of dividend payers in the French market (1.79%).
High Dividend: VETO's dividend (0.7%) is low compared to the top 25% of dividend payers in the French market (5.46%).
Stability and Growth of Payments
Stable Dividend: VETO is not paying a notable dividend for the French market, therefore no need to check if payments are stable.
Growing Dividend: VETO is not paying a notable dividend for the French market, therefore no need to check if payments are increasing.
Current Payout to Shareholders
Dividend Coverage: VETO is not paying a notable dividend for the French market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of VETO's dividend in 3 years as they are not forecast to pay a notable one for the French market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Matthieu Frechin (50yo)
Mr. Matthieu Frechin has been the Chief Executive Officer at Vétoquinol SA since April 01, 2010. Mr. Frechin served as Deputy Chief Executive Officer of Vétoquinol SA from August 21, 2006 and also served a ...
CEO Compensation Analysis
Compensation vs Market: Matthieu's total compensation ($USD488.91K) is below average for companies of similar size in the French market ($USD799.62K).
Compensation vs Earnings: Matthieu's compensation has been consistent with company performance over the past year.
|CEO & Director||10.08yrs||€448.82k||no data|
|Group COO & Deputy GM||0.33yr||€359.85k||no data|
|Group Director of Finance & Legal||9.5yrs||no data||no data|
|Group Chief Operations Officer||0.083yr||no data||no data|
|Chief Scientific Officer||4.5yrs||no data||no data|
|Group Director of Marketing & Communication||no data||no data||no data|
|Group Director of Human Resources||no data||no data||no data|
Experienced Management: VETO's management team is considered experienced (4.5 years average tenure).
|CEO & Director||10.08yrs||€448.82k||no data|
|Chairman of the Board||40.33yrs||€159.06k||4.18% €26.7m|
|Independent Director||12.92yrs||€17.00k||no data|
|Independent Director||10.75yrs||€17.00k||no data|
|Independent Director||7yrs||€17.00k||no data|
|Independent Director||2yrs||no data||no data|
Experienced Board: VETO's board of directors are seasoned and experienced ( 13.5 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Vetoquinol SA's company bio, employee growth, exchange listings and data sources
- Name: Vetoquinol SA
- Ticker: VETO
- Exchange: ENXTPA
- Founded: 1933
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: €638.918m
- Shares outstanding: 11.83m
- Website: https://www.vetoquinol.com
Number of Employees
- Vetoquinol SA
- 34 rue du ChEne-Sainte-Anne
- Franche Comté
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|VETO||ENXTPA (Euronext Paris)||Yes||Ordinary Shares||FR||EUR||Nov 2006|
|0O1O||LSE (London Stock Exchange)||Yes||Ordinary Shares||GB||EUR||Nov 2006|
Vetoquinol SA, a veterinary pharmaceutical company, designs, develops, and sells veterinary drugs and non-medicinal products in Europe, the Americas, and the Asia Pacific region. It provides products in the areas of pain management, anti-infective, cardiology-nephrology, care and hygiene, antiparasiticides, behavior, internal medicine, and reproduction for cats, dogs, cattle, and pigs. The company was founded in 1933 and is headquartered in Lure, France. Vetoquinol SA is a subsidiary of Soparfin SCA.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/05/25 07:04|
|End of Day Share Price||2020/05/22 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.